The Antibody Humanization Market is gaining importance as pharmaceutical and biotechnology companies expand their development of antibody-based therapeutics. Antibody humanization helps reduce the immunogenicity of non-human antibodies while preserving their target-binding properties, making it an important step in antibody engineering and therapeutic development.

Affinity maturation complements antibody humanization by improving the binding affinity and performance of antibody candidates. As antibody development becomes increasingly specialized, companies are turning to dedicated antibody humanization services and platforms to access technical expertise and advanced engineering capabilities without developing all these resources internally.

The market is also being influenced by advances in AI, machine learning, computational antibody design and automated screening. These technologies can support faster identification and optimization of promising antibody candidates.

The global Antibody Humanization Market was valued at USD 5.7 billion in 2024 and is projected to reach USD 14.9 billion by 2035, growing at a CAGR of 9.1%. Increasing antibody drug development activity and demand for specialized antibody engineering services are expected to support continued market growth.

For detailed market size, forecasts, competitive analysis, service and platform insights, explore the Antibody Humanization Market report by Roots Analysis.